Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | TYMP | P19971 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL197295 | 0.78 | GLA (0.42) | KDM4ETSHRGLASMN1; SMN2ALDH1A1 | |
| SCHEMBL5294936 | 0.78 | — | — | |
| SCHEMBL28132579 | 0.78 | — | — | |
| SCHEMBL2104341 | 0.76 | SMN1; SMN2 (0.40) | HSD17B10ALOX15SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL9869781 | 0.75 | KEAP1 (0.48) | KDM4ETSHRUSP2SMN1; SMN2ALDH1A1 | |
| SCHEMBL10000708 | 0.73 | PAOX (0.34) | KDM4ETSHRGLAALDH1A1TDP1 | |
| SCHEMBL5236146 | 0.73 | SMN1; SMN2 (0.34) | HSD17B10SMN1; SMN2ANPEP | |
| SCHEMBL443253 | 0.73 | PAOX (0.34) | KDM4ETSHRGLAALDH1A1TDP1 | |
| SCHEMBL14361231 | 0.72 | POLB (0.54) | KDM4EHSD17B10GLAALDH1A1TDP1 | |
| SCHEMBL347618 | 0.72 | USP2 (0.44) | KDM4EHSD17B10ALOX15TSHRUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078401-B2 | Thiophenylaminoimidazolines as IP antagonists | ROCHE PALO ALTO LLC (US) | 2006-07-18 | — | — | US | claimed |
| EP-1656350-A2 | THIOPHENYLAMINOIMIDAZOLINES AS PROSTAGLANDIN I2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | claimed |
| US-20050020648-A1 | Thiophenylaminoimidazolines as IP antagonists | ROCHE PALO ALTO LLC | 2005-01-27 | — | — | US | claimed |
| WO-2005005394-A2 | THIOPHENYLAMINOIMIDAZOLINES AS PROSTAGLANDIN I2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-01-20 | — | — | WO | claimed |
| US-10532985-B2 | Heterocycle and carbocycle derivatives having TRKA inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2020-01-14 | — | — | US | disclosed |
| US-10160727-B2 | Heterocycle and carbocycle derivatives having TrkA inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2018-12-25 | — | — | US | disclosed |
| US-9758513-B2 | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
| US-20170240512-A1 | HETEROCYCLE AND CARBOCYCLE DERIVATIVES HAVING TRKA INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-08-24 | — | — | US | disclosed |
| US-9725442-B2 | Heterocyclic derivative having PGD2 receptor antagonist activity | SHIONOGI & CO., LTD. (JP) | 2017-08-08 | — | — | US | disclosed |
| WO-2017061534-A1 | DIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2017-04-13 | — | — | WO | disclosed |
| US-20170073337-A1 | DIHYDROTHIAZINE AND DIHYDROOXAZINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-03-16 | — | — | US | disclosed |
| US-20170066759-A1 | AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY | SHIONOGI & CO (JP) | 2017-03-09 | — | — | US | disclosed |
| US-7192968-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-7078401-B2 | Thiophenylaminoimidazolines as IP antagonists | ROCHE PALO ALTO LLC (US) | 2006-07-18 | — | — | US | disclosed |
| EP-1656350-A2 | THIOPHENYLAMINOIMIDAZOLINES AS PROSTAGLANDIN I2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20060004009-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| US-20050020648-A1 | Thiophenylaminoimidazolines as IP antagonists | ROCHE PALO ALTO LLC | 2005-01-27 | — | — | US | disclosed |
| WO-2005005394-A2 | THIOPHENYLAMINOIMIDAZOLINES AS PROSTAGLANDIN I2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-01-20 | — | — | WO | disclosed |
| US-20040122063-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1270557-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020648-A1 | Thiophenylaminoimidazolines as IP antagonists | TBXA2R, MRGPRX2, MRGPRX1 | KDM4E 4684/4885HSD17B10 4363/4885ALOX15 1726/4885 |
| US-20060004009-A1 | Ethylenediamine derivatives | F2, ECE1, MLLT1 | KDM4E 740/4885HSD17B10 3259/4885ALOX15 2113/4885 |
| US-10160727-B2 | Heterocycle and carbocycle derivatives having TrkA inhibitory activity | NR5A2, NPY5R, MC5R | KDM4E 737/4885HSD17B10 3440/4885ALOX15 2043/4885 |
| US-20170066759-A1 | AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY | TRPV4, TRPC4, TRPV2 | KDM4E 891/4885HSD17B10 2882/4885ALOX15 3551/4885 |
| US-20170073337-A1 | DIHYDROTHIAZINE AND DIHYDROOXAZINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | BACE1, BACE2, APP | KDM4E 2950/4885HSD17B10 255/4885ALOX15 1115/4885 |
| US-10532985-B2 | Heterocycle and carbocycle derivatives having TRKA inhibitory activity | NR5A2, NPY5R, MC5R | KDM4E 737/4885HSD17B10 3440/4885ALOX15 2043/4885 |
| US-20170240512-A1 | HETEROCYCLE AND CARBOCYCLE DERIVATIVES HAVING TRKA INHIBITORY ACTIVITY | NR5A2, NPY5R, MC5R | KDM4E 737/4885HSD17B10 3440/4885ALOX15 2043/4885 |
| US-20040122063-A1 | Ethylenediamine derivatives | ECE1, F2, ECE2 | KDM4E 645/4885HSD17B10 3784/4885ALOX15 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.